Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.

@article{Lapchak2004CoadministrationON,
  title={Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.},
  author={Paul A. Lapchak and Donghuan Song and Jiandong Wei and Justin A. Zivin},
  journal={Experimental neurology},
  year={2004},
  volume={188 2},
  pages={279-85}
}
Currently, the only FDA-approved treatment for acute ischemic stroke (AIS) is the thrombolytic, tissue plasminogen activator (tPA; alteplase; activase). It has been proposed that both the spin trap agent NXY-059 (cerovive) and tenecteplase (TNK-tPA), which are currently in phase II clinical trials, may also be useful for the treatment of ischemic stroke. However, there is little information available concerning the dose-response profiles or therapeutic window for NXY-059 in a validated embolic… CONTINUE READING